Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients

Bone Marrow Transplantation
N KrögerA R Zander

Abstract

We compared fractionated total body irradiation (12 Gy)/cyclophosphamide (120 mg/kg) with busulfan (16 mg/kg)/cyclophosphamide (120 mg/kg) as preparative therapy in unrelated donor stem cell transplantation of CML patients. Fifty patients with CML (1.CP = 46; aP = 4) and a median age of 36 years (range 16-52) were enrolled in this sequential trial between 1994 and 1999. In both groups patients were well balanced with respect to age, disease status, stem cell source and CMV status. All patients received standard doses of cyclosporin A, methotrexate and anti-thymocyte globulin (ATG) as GVHD prophylaxis. No graft failures occurred in either group. The median day of leukocyte engraftment was earlier in the Bu/Cy than in the TBI/Cy group (day 15 vs 17; P = 0.006). The incidence of grade II-IV GVHD was 40% in the TBI/Cy and 36% in the Bu/Cy group, whereas severe grade III/IV GVHD was only observed in 12% of patients in both groups. The incidence of chronic GVHD (limited and extensive) at 1 year was higher in the Bu/Cy arm (65% vs 30%; P = 0.02). More toxicity grade I/II of the liver (88% vs 44%; P = 0.002) and more hemorrhagic cystitis (32% vs 8%; P = 0.02) were observed in the Bu/Cy regimen. Seven relapses in the TBI and no relapse ...Continue Reading

References

Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S I BearmanE D Thomas
Mar 4, 1993·The New England Journal of Medicine·N A KernanJ McCullough
Apr 2, 1998·The New England Journal of Medicine·J A HansenC Anasetti
May 25, 1999·Bone Marrow Transplantation·A R ZanderH Kabisch

❮ Previous
Next ❯

Citations

Oct 17, 2003·Hematology/oncology Clinics of North America·Alan S Wayne, A J Barrett
Jul 30, 2014·Bone Marrow Transplantation·C R KelseyL W Jones
Nov 19, 2010·Expert Review of Hematology·Pasquale Niscola
Sep 28, 2010·Expert Review of Hematology·Boglarka GyurkoczaRainer F Storb
Nov 3, 2010·International Journal of Radiation Oncology, Biology, Physics·Mete YeginerBulent Aydogan
Dec 1, 2009·Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists·Audrey H ZhuangJeffrey Y C Wong
Jul 21, 2009·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·T ZilliM Ozsahin
Jan 18, 2006·Urology·Matthew BraaschManoj Monga
Feb 13, 2003·Pediatric Clinics of North America·Ulrike Reiss, Ellen Bolotin
Apr 22, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Haixia FuXiaojun Huang
Sep 4, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul WoodardMary Eapen
Mar 24, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Scott R SolomonAsad Bashey
Oct 12, 2010·International Journal of Radiation Oncology, Biology, Physics·Chris R KelseyLawrence B Marks
May 10, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Wei TangJiong Hu
Oct 9, 2018·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Amir Ali HamidiehArdeshir Ghavamzadeh
Aug 2, 2017·Annals of Rehabilitation Medicine·Soojae KimSungju Jee
May 25, 2021·Journal of Applied Clinical Medical Physics·Akira IsobeKeisuke Sasai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.